N-of-1 Tailored Combination Therapy Matched to the Molecular Alterations, Facilitated by Personalised Dosing, Is Associated with Safety and Activity By Ogkologos - January 23, 2026 271 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the I-PREDICT study Source RELATED ARTICLESMORE FROM AUTHOR Weight Loss Treatments Linked to Lower Risk of Obesity-Related Cancers in People Without Diabetes EMA Recommends Granting a Marketing Authorisation for Camizestrant ESMO Calls for the Ring-Fenced Funding of Health Under the 2028-2034 Long-Term Budget of the EU, the Multiannual Financial Framework (MFF) MOST POPULAR pCR Correlates with RFS and OS with Neoadjuvant Therapy in Stage... February 16, 2021 ASCO Annual Meeting 2023: Improving Outcomes in Glioma, Hodgkin Lymphoma, Lung... June 4, 2023 Opportunity and mentorship: Our new PhD programme aiming to open-up academia... July 22, 2022 Vepdegestrant Results in Longer PFS Than Fulvestrant in Previously Treated Patients... June 4, 2025 Load more HOT NEWS EMA Recommends Extension of Indications for Durvalumab in the Management of... Genomic Alterations Enriched in Young Women with HR-positive, HER2-negative Early Breast... Spotlight On: Exercise Physiologists in Cancer Care Regular Exercise May Boost Immune Response and Improve Immunotherapy in Breast...
